+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Opioids Market by Product Type and Application: Global Opportunity Analysis and Industry Forecast, 2021-2030

  • PDF Icon

    Report

  • 213 Pages
  • May 2022
  • Region: Global
  • Allied Market Research
  • ID: 5578251
Description Jump to:

The global opioids market was valued at $4,412.48 million in 2020, and is projected to reach $6,060.17 million by 2030, registering a CAGR of 3.2% from 2021 to 2030.



Opioids are pain relievers because they include substances that relax muscles and alleviate pain and stress. Prescription opioids are primarily used to treat moderate to severe pain, while some opioids can be used to alleviate coughing and diarrhea. Hydrocodone, oxycodone, codeine, fentanyl, methadone, morphine, and other pharmaceutical opioids are among them. Opioids are the most commonly prescribed pain relievers for people suffering from moderate to severe chronic pain. These analgesics are used to treat severe continuous pain in individuals with terminal conditions and to manage pain in cancer patients.

The growth of the global opioids market is driven by alarming increase in incidence of orthopedic diseases & chronic pain. Furthermore, rise in disposable income and surge in geriatric population are expected to propel the growth of the global opioids market. However, emergence and legalization of cannabis as an alternative to opioids impede the growth of the market. On the contrary, increase in consumption of opioids analgesic for pain management in developing countries is anticipated to create lucrative opportunities for market expansion in the near future.

The opioids market is segmented on the basis of type of product, application, and region. According to type of product, the market is classified into codeine, fentanyl, oxycodone, methadone, morphine, hydrocodone, and others. On the basis of application, the market is divided into pain management, cough treatment, and diarrhea treatment. The pain management segment is further divided into neuropathic pain, migraine, back pain, osteoarthritis pain, and cancer pain. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The major companies profiled in the report include Purdue Pharma LP, AstraZeneca Plc., C.H. Boehringer Sohn Ag and Ko. Kg, Johnson and Johnson Inc., Sanofi S.A, Mallinckrodt Pharmaceuticals, Endo Pharmaceuticals Inc., Pfizer, Inc., Sun Pharmaceuticals, and Teva Pharmaceuticals.

KEY BENEFITS FOR STAKEHOLDERS

  • The study provides an in-depth analysis of the global opioids market and current & future trends to elucidate the imminent investment pockets
  • Information about key drivers, restrains, and opportunities and their impact analysis on the market size is provided
  • Porter’s five forces analysis illustrates the potency of buyers and suppliers operating in the industry
  • The quantitative analysis of the global market from 2021 to 2030 is provided to determine the market potential

By Product

  • Codeine
  • Fentanyl
  • Oxycodone
  • Methadone
  • Morphine
  • Hydrocodone
  • Others

By Applications

  • Pain management
  • Cough treatment
  • Diarrhea treatment

By Region

  • North America
  • US
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

KEY PLAYERS

  • AstraZeneca PLC
  • Purdue Pharma LP
  • Johnson and Johnson Inc
  • Sanofi SA
  • Mallinckrodt Pharmaceuticals
  • Endo Pharmaceuticals Inc
  • Pfizer, Inc
  • Sun Pharmaceuticals
  • Teva Pharmaceuticals
  • C.H Boehringer Sohn Ag and ko Kg

 

Please note:

  • Online Access price format is valid for 60 days access. Printing is not enabled.
  • PDF Single and Enterprise price formats enable printing.

 

Table of Contents

Chapter 1: Introduction
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
Chapter 2: Executive Summary
2.1. Cxo Perspective
Chapter 3: Market Landscape
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power Among Buyers
3.4. Market Share Analysis/Top Player Positioning
3.4.1. Market Share Analysis/Top Player Positioning 2020
3.5. Market Dynamics
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
3.6. Covid-19 Impact Analysis
Chapter 4: Opioids Market, by Product Type
4.1. Market Overview
4.1.1 Market Size and Forecast, by Product Type
4.2. Fentanyl
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, by Region
4.2.3. Market Share Analysis, by Country
4.3. Oxycodone
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, by Region
4.3.3. Market Share Analysis, by Country
4.4. Methadone
4.4.1. Key Market Trends, Growth Factors and Opportunities
4.4.2. Market Size and Forecast, by Region
4.4.3. Market Share Analysis, by Country
4.5. Morphine
4.5.1. Key Market Trends, Growth Factors and Opportunities
4.5.2. Market Size and Forecast, by Region
4.5.3. Market Share Analysis, by Country
4.6. Hydrocodone
4.6.1. Key Market Trends, Growth Factors and Opportunities
4.6.2. Market Size and Forecast, by Region
4.6.3. Market Share Analysis, by Country
4.7. Others
4.7.1. Key Market Trends, Growth Factors and Opportunities
4.7.2. Market Size and Forecast, by Region
4.7.3. Market Share Analysis, by Country
Chapter 5: Opioids Market, by Application
5.1. Market Overview
5.1.1 Market Size and Forecast, by Application
5.2. Pain Management
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.2.2. Market Size and Forecast, by Region
5.2.3. Market Share Analysis, by Country
5.3. Cough Treatment
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.3.2. Market Size and Forecast, by Region
5.3.3. Market Share Analysis, by Country
5.4. Diarrhea Treatment
5.4.1. Key Market Trends, Growth Factors and Opportunities
5.4.2. Market Size and Forecast, by Region
5.4.3. Market Share Analysis, by Country
Chapter 6: Opioids Market, by Region
6.1. Market Overview
6.1.1 Market Size and Forecast, by Region
6.2. North America
6.2.1. Key Market Trends and Opportunities
6.2.2. Market Size and Forecast, by Product Type
6.2.3. Market Size and Forecast, by Application
6.2.4. Market Size and Forecast, by Country
6.2.5. U. S. Opioids Market
6.2.5.1. Market Size and Forecast, by Product Type
6.2.5.2. Market Size and Forecast, by Application
6.2.6. Canada Opioids Market
6.2.6.1. Market Size and Forecast, by Product Type
6.2.6.2. Market Size and Forecast, by Application
6.2.7. Mexico Opioids Market
6.2.7.1. Market Size and Forecast, by Product Type
6.2.7.2. Market Size and Forecast, by Application
6.3. Europe
6.3.1. Key Market Trends and Opportunities
6.3.2. Market Size and Forecast, by Product Type
6.3.3. Market Size and Forecast, by Application
6.3.4. Market Size and Forecast, by Country
6.3.5. Germany Opioids Market
6.3.5.1. Market Size and Forecast, by Product Type
6.3.5.2. Market Size and Forecast, by Application
6.3.6. France Opioids Market
6.3.6.1. Market Size and Forecast, by Product Type
6.3.6.2. Market Size and Forecast, by Application
6.3.7. Uk Opioids Market
6.3.7.1. Market Size and Forecast, by Product Type
6.3.7.2. Market Size and Forecast, by Application
6.3.8. Italy Opioids Market
6.3.8.1. Market Size and Forecast, by Product Type
6.3.8.2. Market Size and Forecast, by Application
6.3.9. Spain Opioids Market
6.3.9.1. Market Size and Forecast, by Product Type
6.3.9.2. Market Size and Forecast, by Application
6.3.10. Rest of Europe Opioids Market
6.3.10.1. Market Size and Forecast, by Product Type
6.3.10.2. Market Size and Forecast, by Application
6.4. Asia-Pacific
6.4.1. Key Market Trends and Opportunities
6.4.2. Market Size and Forecast, by Product Type
6.4.3. Market Size and Forecast, by Application
6.4.4. Market Size and Forecast, by Country
6.4.5. Japan Opioids Market
6.4.5.1. Market Size and Forecast, by Product Type
6.4.5.2. Market Size and Forecast, by Application
6.4.6. China Opioids Market
6.4.6.1. Market Size and Forecast, by Product Type
6.4.6.2. Market Size and Forecast, by Application
6.4.7. Australia Opioids Market
6.4.7.1. Market Size and Forecast, by Product Type
6.4.7.2. Market Size and Forecast, by Application
6.4.8. India Opioids Market
6.4.8.1. Market Size and Forecast, by Product Type
6.4.8.2. Market Size and Forecast, by Application
6.4.9. South Korea Opioids Market
6.4.9.1. Market Size and Forecast, by Product Type
6.4.9.2. Market Size and Forecast, by Application
6.4.10. Rest of Asia-Pacific Opioids Market
6.4.10.1. Market Size and Forecast, by Product Type
6.4.10.2. Market Size and Forecast, by Application
6.5. LAMEA
6.5.1. Key Market Trends and Opportunities
6.5.2. Market Size and Forecast, by Product Type
6.5.3. Market Size and Forecast, by Application
6.5.4. Market Size and Forecast, by Country
6.5.5. Brazil Opioids Market
6.5.5.1. Market Size and Forecast, by Product Type
6.5.5.2. Market Size and Forecast, by Application
6.5.6. Saudi Arabia Opioids Market
6.5.6.1. Market Size and Forecast, by Product Type
6.5.6.2. Market Size and Forecast, by Application
6.5.7. South Africa Opioids Market
6.5.7.1. Market Size and Forecast, by Product Type
6.5.7.2. Market Size and Forecast, by Application
6.5.8. Rest of LAMEA Opioids Market
6.5.8.1. Market Size and Forecast, by Product Type
6.5.8.2. Market Size and Forecast, by Application
Chapter 7: Company Profiles
7.1. Boehringer Ingelheim Group
7.1.1. Company Overview
7.1.2. Key Executives
7.1.3. Company Snapshot
7.1.4. Operating Business Segments
7.1.5. Product Portfolio
7.1.6. Business Performance
7.1.7. Key Strategic Moves and Developments
7.2. Astrazeneca plc
7.2.1. Company Overview
7.2.2. Key Executives
7.2.3. Company Snapshot
7.2.4. Operating Business Segments
7.2.5. Product Portfolio
7.2.6. Business Performance
7.2.7. Key Strategic Moves and Developments
7.3. Endo Pharmaceuticals, Inc
7.3.1. Company Overview
7.3.2. Key Executives
7.3.3. Company Snapshot
7.3.4. Operating Business Segments
7.3.5. Product Portfolio
7.3.6. Business Performance
7.3.7. Key Strategic Moves and Developments
7.4. Johnson and Johnson
7.4.1. Company Overview
7.4.2. Key Executives
7.4.3. Company Snapshot
7.4.4. Operating Business Segments
7.4.5. Product Portfolio
7.4.6. Business Performance
7.4.7. Key Strategic Moves and Developments
7.5. Mallinckrodt plc
7.5.1. Company Overview
7.5.2. Key Executives
7.5.3. Company Snapshot
7.5.4. Operating Business Segments
7.5.5. Product Portfolio
7.5.6. Business Performance
7.5.7. Key Strategic Moves and Developments
7.6. Pfizer Inc
7.6.1. Company Overview
7.6.2. Key Executives
7.6.3. Company Snapshot
7.6.4. Operating Business Segments
7.6.5. Product Portfolio
7.6.6. Business Performance
7.6.7. Key Strategic Moves and Developments
7.7. Purdue Pharma L. P
7.7.1. Company Overview
7.7.2. Key Executives
7.7.3. Company Snapshot
7.7.4. Operating Business Segments
7.7.5. Product Portfolio
7.7.6. Business Performance
7.7.7. Key Strategic Moves and Developments
7.8. Sanofi
7.8.1. Company Overview
7.8.2. Key Executives
7.8.3. Company Snapshot
7.8.4. Operating Business Segments
7.8.5. Product Portfolio
7.8.6. Business Performance
7.8.7. Key Strategic Moves and Developments
7.9. Sun Pharmaceutical Industries Ltd
7.9.1. Company Overview
7.9.2. Key Executives
7.9.3. Company Snapshot
7.9.4. Operating Business Segments
7.9.5. Product Portfolio
7.9.6. Business Performance
7.9.7. Key Strategic Moves and Developments
7.10. Teva Pharmaceutical Industries Limited
7.10.1. Company Overview
7.10.2. Key Executives
7.10.3. Company Snapshot
7.10.4. Operating Business Segments
7.10.5. Product Portfolio
7.10.6. Business Performance
7.10.7. Key Strategic Moves and Developments
List of Tables
Table 1. Global Opioids Market, by Product Type, 2020-2030 ($Million)
Table 2. Global Opioids Market for Fentanyl, by Region, 2020-2030 ($Million)
Table 3. Global Opioids Market for Oxycodone, by Region, 2020-2030 ($Million)
Table 4. Global Opioids Market for Methadone, by Region, 2020-2030 ($Million)
Table 5. Global Opioids Market for Morphine, by Region, 2020-2030 ($Million)
Table 6. Global Opioids Market for Hydrocodone, by Region, 2020-2030 ($Million)
Table 7. Global Opioids Market for Others, by Region, 2020-2030 ($Million)
Table 8. Global Opioids Market, by Application, 2020-2030 ($Million)
Table 9. Global Opioids Market for Pain Management, by Region, 2020-2030 ($Million)
Table 10. Global Opioids Market for Cough Treatment, by Region, 2020-2030 ($Million)
Table 11. Global Opioids Market for Diarrhea Treatment, by Region, 2020-2030 ($Million)
Table 12. Global Opioids Market, by Region, 2020-2030 ($Million)
Table 13. North America Opioids, by Product Type, 2020-2030 ($Million)
Table 14. North America Opioids, by Application, 2020-2030 ($Million)
Table 15. U.S Opioids, by Product Type, 2020-2030 ($Million)
Table 16. U.S Opioids, by Application, 2020-2030 ($Million)
Table 17. Canada Opioids, by Product Type, 2020-2030 ($Million)
Table 18. Canada Opioids, by Application, 2020-2030 ($Million)
Table 19. Mexico Opioids, by Product Type, 2020-2030 ($Million)
Table 20. Mexico Opioids, by Application, 2020-2030 ($Million)
Table 21. Europe Opioids, by Product Type, 2020-2030 ($Million)
Table 22. Europe Opioids, by Application, 2020-2030 ($Million)
Table 23. Germany Opioids, by Product Type, 2020-2030 ($Million)
Table 24. Germany Opioids, by Application, 2020-2030 ($Million)
Table 25. France Opioids, by Product Type, 2020-2030 ($Million)
Table 26. France Opioids, by Application, 2020-2030 ($Million)
Table 27. Uk Opioids, by Product Type, 2020-2030 ($Million)
Table 28. Uk Opioids, by Application, 2020-2030 ($Million)
Table 29. Italy Opioids, by Product Type, 2020-2030 ($Million)
Table 30. Italy Opioids, by Application, 2020-2030 ($Million)
Table 31. Spain Opioids, by Product Type, 2020-2030 ($Million)
Table 32. Spain Opioids, by Application, 2020-2030 ($Million)
Table 33. Rest of Europe Opioids, by Product Type, 2020-2030 ($Million)
Table 34. Rest of Europe Opioids, by Application, 2020-2030 ($Million)
Table 35. Asia-Pacific Opioids, by Product Type, 2020-2030 ($Million)
Table 36. Asia-Pacific Opioids, by Application, 2020-2030 ($Million)
Table 37. Japan Opioids, by Product Type, 2020-2030 ($Million)
Table 38. Japan Opioids, by Application, 2020-2030 ($Million)
Table 39. China Opioids, by Product Type, 2020-2030 ($Million)
Table 40. China Opioids, by Application, 2020-2030 ($Million)
Table 41. Australia Opioids, by Product Type, 2020-2030 ($Million)
Table 42. Australia Opioids, by Application, 2020-2030 ($Million)
Table 43. India Opioids, by Product Type, 2020-2030 ($Million)
Table 44. India Opioids, by Application, 2020-2030 ($Million)
Table 45. South Korea Opioids, by Product Type, 2020-2030 ($Million)
Table 46. South Korea Opioids, by Application, 2020-2030 ($Million)
Table 47. Rest of Asia-Pacific Opioids, by Product Type, 2020-2030 ($Million)
Table 48. Rest of Asia-Pacific Opioids, by Application, 2020-2030 ($Million)
Table 49. Lamea Opioids, by Product Type, 2020-2030 ($Million)
Table 50. Lamea Opioids, by Application, 2020-2030 ($Million)
Table 51. Brazil Opioids, by Product Type, 2020-2030 ($Million)
Table 52. Brazil Opioids, by Application, 2020-2030 ($Million)
Table 53. Saudi Arabia Opioids, by Product Type, 2020-2030 ($Million)
Table 54. Saudi Arabia Opioids, by Application, 2020-2030 ($Million)
Table 55. South Africa Opioids, by Product Type, 2020-2030 ($Million)
Table 56. South Africa Opioids, by Application, 2020-2030 ($Million)
Table 57. Rest of LAMEA Opioids, by Product Type, 2020-2030 ($Million)
Table 58. Rest of LAMEA Opioids, by Application, 2020-2030 ($Million)
Table 59. Boehringer Ingelheim Group: Key Executives
Table 60. Boehringer Ingelheim Group: Company Snapshot
Table 61. Boehringer Ingelheim Group: Operating Segments
Table 62. Boehringer Ingelheim Group: Product Portfolio
Table 63. Boehringer Ingelheim Group: Key Strategic Moves and Developments
Table 64. Astrazeneca plc: Key Executives
Table 65. Astrazeneca plc: Company Snapshot
Table 66. Astrazeneca plc: Operating Segments
Table 67. Astrazeneca plc: Product Portfolio
Table 68. Astrazeneca plc: Key Strategic Moves and Developments
Table 69. Endo Pharmaceuticals, Inc: Key Executives
Table 70. Endo Pharmaceuticals, Inc: Company Snapshot
Table 71. Endo Pharmaceuticals, Inc: Operating Segments
Table 72. Endo Pharmaceuticals, Inc: Product Portfolio
Table 73. Endo Pharmaceuticals, Inc: Key Strategic Moves and Developments
Table 74. Johnson and Johnson: Key Executives
Table 75. Johnson and Johnson: Company Snapshot
Table 76. Johnson and Johnson: Operating Segments
Table 77. Johnson and Johnson: Product Portfolio
Table 78. Johnson and Johnson: Key Strategic Moves and Developments
Table 79. Mallinckrodt plc: Key Executives
Table 80. Mallinckrodt plc: Company Snapshot
Table 81. Mallinckrodt plc: Operating Segments
Table 82. Mallinckrodt plc: Product Portfolio
Table 83. Mallinckrodt plc: Key Strategic Moves and Developments
Table 84. Pfizer Inc: Key Executives
Table 85. Pfizer Inc: Company Snapshot
Table 86. Pfizer Inc: Operating Segments
Table 87. Pfizer Inc: Product Portfolio
Table 88. Pfizer Inc: Key Strategic Moves and Developments
Table 89. Purdue Pharma L. P: Key Executives
Table 90. Purdue Pharma L. P: Company Snapshot
Table 91. Purdue Pharma L. P: Operating Segments
Table 92. Purdue Pharma L. P: Product Portfolio
Table 93. Purdue Pharma L. P: Key Strategic Moves and Developments
Table 94. Sanofi: Key Executives
Table 95. Sanofi: Company Snapshot
Table 96. Sanofi: Operating Segments
Table 97. Sanofi: Product Portfolio
Table 98. Sanofi: Key Strategic Moves and Developments
Table 99. Sun Pharmaceutical Industries Ltd: Key Executives
Table 100. Sun Pharmaceutical Industries Ltd: Company Snapshot
Table 101. Sun Pharmaceutical Industries Ltd: Operating Segments
Table 102. Sun Pharmaceutical Industries Ltd: Product Portfolio
Table 103. Sun Pharmaceutical Industries Ltd: Key Strategic Moves and Developments
Table 104. Teva Pharmaceutical Industries Limited: Key Executives
Table 105. Teva Pharmaceutical Industries Limited: Company Snapshot
Table 106. Teva Pharmaceutical Industries Limited: Operating Segments
Table 107. Teva Pharmaceutical Industries Limited: Product Portfolio
Table 108. Teva Pharmaceutical Industries Limited: Key Strategic Moves and Developments
List of Figures
Figure 1. Global Opioids Market Segmentation
Figure 2. Global Opioids Market
Figure 3. Segmentation Opioids Market
Figure 4. Top Investment Pocket in Opioids Market
Figure 5. Top Winning Strategies, 2019-2021*
Figure 6. Top Winning Strategies, by Development, 2019-2021(%)
Figure 7. Top Winning Strategies, by Company, 2019-2021*
Figure 8. Moderate Bargaining Power of Buyers
Figure 9. Moderate Bargaining Power of Suppliers
Figure 10. Moderate Threat of New Entrants
Figure 11. Low Threat of Substitution
Figure 12. High Competitive Rivalry
Figure 13. Top Player Positioning, 2020
Figure 14. Market Share Analysis, 2020
Figure 15. Restraints and Drivers: Opioids Market
Figure 16. Opioids Market Segmentation, by Product Type
Figure 17. Opioids Market for Fentanyl, by Country, 2020-2030 ($ Million)
Figure 18. Opioids Market for Oxycodone, by Country, 2020-2030 ($ Million)
Figure 19. Opioids Market for Methadone, by Country, 2020-2030 ($ Million)
Figure 20. Opioids Market for Morphine, by Country, 2020-2030 ($ Million)
Figure 21. Opioids Market for Hydrocodone, by Country, 2020-2030 ($ Million)
Figure 22. Opioids Market for Others, by Country, 2020-2030 ($ Million)
Figure 23. Opioids Market Segmentation, by Application
Figure 24. Opioids Market for Pain Management, by Country, 2020-2030 ($ Million)
Figure 25. Opioids Market for Cough Treatment, by Country, 2020-2030 ($ Million)
Figure 26. Opioids Market for Diarrhea Treatment, by Country, 2020-2030 ($ Million)
Figure 27. Boehringer Ingelheim Group: Net Sales, 2018-2020 ($ Million)
Figure 28. Boehringer Ingelheim Group: Revenue Share, by Segment, 2020 (%)
Figure 29. Boehringer Ingelheim Group: Revenue Share, by Region, 2020 (%)
Figure 30. Astrazeneca plc: Net Sales, 2018-2020 ($ Million)
Figure 31. Astrazeneca plc: Revenue Share, by Segment, 2020 (%)
Figure 32. Astrazeneca plc: Revenue Share, by Region, 2020 (%)
Figure 33. Endo Pharmaceuticals, Inc: Net Sales, 2018-2020 ($ Million)
Figure 34. Endo Pharmaceuticals, Inc: Revenue Share, by Segment, 2020 (%)
Figure 35. Endo Pharmaceuticals, Inc: Revenue Share, by Region, 2020 (%)
Figure 36. Johnson and Johnson: Net Sales, 2018-2020 ($ Million)
Figure 37. Johnson and Johnson: Revenue Share, by Segment, 2020 (%)
Figure 38. Johnson and Johnson: Revenue Share, by Region, 2020 (%)
Figure 39. Mallinckrodt plc: Net Sales, 2018-2020 ($ Million)
Figure 40. Mallinckrodt plc: Revenue Share, by Segment, 2020 (%)
Figure 41. Mallinckrodt plc: Revenue Share, by Region, 2020 (%)
Figure 42. Pfizer Inc: Net Sales, 2018-2020 ($ Million)
Figure 43. Pfizer Inc: Revenue Share, by Segment, 2020 (%)
Figure 44. Pfizer Inc: Revenue Share, by Region, 2020 (%)
Figure 45. Purdue Pharma L. P: Net Sales, 2018-2020 ($ Million)
Figure 46. Purdue Pharma L. P: Revenue Share, by Segment, 2020 (%)
Figure 47. Purdue Pharma L. P: Revenue Share, by Region, 2020 (%)
Figure 48. Sanofi: Net Sales, 2018-2020 ($ Million)
Figure 49. Sanofi: Revenue Share, by Segment, 2020 (%)
Figure 50. Sanofi: Revenue Share, by Region, 2020 (%)
Figure 51. Sun Pharmaceutical Industries Ltd: Net Sales, 2018-2020 ($ Million)
Figure 52. Sun Pharmaceutical Industries Ltd: Revenue Share, by Segment, 2020 (%)
Figure 53. Sun Pharmaceutical Industries Ltd: Revenue Share, by Region, 2020 (%)
Figure 54. Teva Pharmaceutical Industries Limited: Net Sales, 2018-2020 ($ Million)
Figure 55. Teva Pharmaceutical Industries Limited: Revenue Share, by Segment, 2020 (%)
Figure 56. Teva Pharmaceutical Industries Limited: Revenue Share, by Region, 2020 (%)

Samples

Loading
LOADING...

Executive Summary

According to a new report titled, “Opioids Market by Product Type and Application: Global Opportunity Analysis and Industry Forecast, 2021-2030,” the opioids market size was valued at $4,412.4 million in 2020, and is projected to reach $6,060.1 million by 2030, registering a CAGR of 3.2% from 2021 to 2030.

Opioids are pain relievers as they include substances that relax muscles and ease pain and stress. The opioid is a prescription drug and known by names such as Actiq, Duragesic, and Sublimaze. Prescription opioids are primarily used to treat moderate to severe pain, while some opioids can be used to alleviate coughing and diarrhea. Hydrocodone, oxycodone, codeine, fentanyl, methadone, morphine, and other pharmaceutical opioids are among them. Opioids are used to decrease pain by increasing the threshold for pain. These analgesics are used to treat severe continuous pain in individuals with terminal conditions and to manage pain in cancer patients.

The growth of the opioid market is majorly driven by surge in consumption of opioid drugs to combat pain and rise in geriatric population that are more prone to orthopedic pain. In addition, upsurge in disposable income in developing economies such as India, China, and others contribute to the growth of the market. However, surge in opioid addiction (opioid crisis) across the globe and implementation of stringent government regulation for opioid prescription are the factors anticipated to hamper the market growth. In addition, increase in death rates owing to the overdose of these drugs is a major factor restraining the market growth. For instance, according to the National Institute of Drug Abuse, more than 130 people in the U.S. die daily because of overdosing of opioids.

By product type, the methadone segment was the major revenue contributor in 2020, and is anticipated to continue this trend during the forecast period, owing to increase in intake of opioids across the globe for pain management. On the other side, the demand for fentanyl is projected to exhibit the fastest opioids market growth during the forecast period, owing to rise in use of fentanyl for the treatment of severe pain after surgeries.

By application, the pain management segment presently dominates the opioids market, and is expected to remain dominant during the forecast period. This segment is expected to exhibit a prominent growth rate, owing to rapid increase in number of patients suffering from chronic headaches, migraine, and backaches across the world, which has considerably boosted the need for opioids across the globe, thereby augmenting the growth of the market.

North America accounted for more than 45.23% of the global opioids market share in 2020, and is expected to remain dominant throughout the forecast period. This was attributed to increase in demand for opioids drugs, rise in number of healthcare expenditure, and increase in the number of surgeries. Asia-Pacific is projected to register the highest CAGR of 3.5% during the forecast period, owing to increase in incidence of population suffering from various diseases such as migraine, arthritis and cancer pain disease and rise in ageing population. In addition, increase in healthcare expenditure offers a lucrative opportunity for the market growth.

The major companies profiled in the report includes, Purdue Pharma, Boehringer Ingelheim, Janssen Pharmaceuticals, Inc., Sanofi, Sun Pharmaceuticals, Mallinckrodt Pharmaceuticals, Endo Pharmaceuticals Inc., Teva pharmaceuticals, Pfizer, Inc.

Key Findings Of The Study


By product type, the Methadone segment is expected to experience rapid growth in the opioids market, and is projected to grow at a CAGR of 3.0% from 2021 to 2030
  • By application, the pain management segment is projected to grow at a CAGR of 29% during the forecast period
  • Region wise, Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 35% during the forecast period

Companies Mentioned

  • Purdue Pharma LP
  • AstraZeneca Plc.
  • C.H. Boehringer Sohn Ag and Ko. Kg
  • Johnson & Johnson, Inc.
  • Sanofi S.A..
  • Mallinckrodt Pharmaceuticals
  • Endo Pharmaceuticals Inc.
  • Pfizer, Inc.
  • Sun Pharmaceuticals
  • Teva Pharmaceuticals.

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages213
PublishedMay 2022
Forecast Period2020 - 2030
Estimated Market Value ( USD ) in 2020 $ 4412.48 million
Forecasted Market Value ( USD ) by 2030 $ 6060.17 million
Compound Annual Growth Rate3.2%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Opioids - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029 - Product Image

Opioids - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

  • Report
  • 125 Pages
  • Global
From
Opioids Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Image

Opioids Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • 292 Pages
  • Global
From
Synthetic Opioid Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application - Product Image

Synthetic Opioid Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application

  • Report
  • 111 Pages
  • Global
From
Opioids Global Market Report 2024 - Product Image

Opioids Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Non-Opioid Pain Patch Global Market Report 2024 - Product Image

Non-Opioid Pain Patch Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.